Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Guoyun Zhu¹, Davide Foletti^{2

3}, Xiaohui Liu², Sheng Ding^{2

4}, Jody Melton Witt^{2

5}, Adela Hasa-Moreno^{2

6}, Mathias Rickert^{2

7}, Charles Holz^{2

5}, Laura Aschenbrenner^{8

9}, Amy H Yang⁸, Eugenia Kraynov¹⁰, Winston Evering⁸, Leslie Obert^{11

12}, Chenyu Lee^{2

13}, Tao Sai², Tina Mistry², Kevin C Lindquist², Thomas Van Blarcom^{2

14}, Pavel Strop^{2

15}, Javier Chaparro-Riggers², Shu-Hui Liu^{2

16}

Affiliations

¹ Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, 230 E. Grand Avenue, South San Francisco, CA, 94080, USA. gzhu108@live.com.
² Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, 230 E. Grand Avenue, South San Francisco, CA, 94080, USA.
³ 23 and Me, 349 Oyster Point Blvd, South San Francisco, CA, 94080, USA.
⁴ Gilead Sciences, 333 Lakeside Drive, Foster City, CA, 94404, USA.
⁵ Grifols Diagnostic Solutions, 6455 Christie Ave B-334C, Emeryville, CA, 94608, USA.
⁶ Kodiak Sciences Inc., 2631 Hanover St, Palo Alto, CA, 94304, USA.
⁷ Applied Molecular Transport, 1 Tower Place, Suite 850, South San Francisco, CA, 94080, USA.
⁸ Drug Safety Research and Development, Pfizer Worldwide Research and Development, 10646 Science Center Dr., San Diego, CA, 92121, USA.
⁹ Covance Inc. Early Phase Development Solutions, 3301 Kinsman Blvd, Madison, WI, 53704, USA.
¹⁰ BioMedicine Design, Pfizer Worldwide Research and Development, 10646 Science Center Dr., San Diego, CA, 92121, USA.
¹¹ Drug Safety Research and Development, Pfizer Worldwide Research and Development, 280 Shennecossett Rd, Groton, CT, 06340, USA.
¹² GSK, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
¹³ Alector, 151 Oyster Point Blvd #300, South San Francisco, CA, 94080, USA.
¹⁴ Allogene Therapeutics, 210 E. Grand Avenue, South San Francisco, CA, 94080, USA.
¹⁵ Bristol-Myers Squibb, 700 Bay Rd suite A, Redwood City, CA, 94063, USA.
¹⁶ Multitude Therapeutics, Abmart, 3698 Haven Avenue Suite A, Redwood City, CA, 94063, USA.

PMID: 31700121
PMCID: PMC6838164
DOI: 10.1038/s41598-019-53130-4

Published Erratum

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Guoyun Zhu et al. Sci Rep. 2019.

. 2019 Nov 8;9(1):16735.

doi: 10.1038/s41598-019-53130-4.

Authors

Affiliations

¹ Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, 230 E. Grand Avenue, South San Francisco, CA, 94080, USA. gzhu108@live.com.
² Pfizer Cancer Immunology Discovery, Pfizer Worldwide Research and Development, 230 E. Grand Avenue, South San Francisco, CA, 94080, USA.
³ 23 and Me, 349 Oyster Point Blvd, South San Francisco, CA, 94080, USA.
⁴ Gilead Sciences, 333 Lakeside Drive, Foster City, CA, 94404, USA.
⁵ Grifols Diagnostic Solutions, 6455 Christie Ave B-334C, Emeryville, CA, 94608, USA.
⁶ Kodiak Sciences Inc., 2631 Hanover St, Palo Alto, CA, 94304, USA.
⁷ Applied Molecular Transport, 1 Tower Place, Suite 850, South San Francisco, CA, 94080, USA.
⁸ Drug Safety Research and Development, Pfizer Worldwide Research and Development, 10646 Science Center Dr., San Diego, CA, 92121, USA.
⁹ Covance Inc. Early Phase Development Solutions, 3301 Kinsman Blvd, Madison, WI, 53704, USA.
¹⁰ BioMedicine Design, Pfizer Worldwide Research and Development, 10646 Science Center Dr., San Diego, CA, 92121, USA.
¹¹ Drug Safety Research and Development, Pfizer Worldwide Research and Development, 280 Shennecossett Rd, Groton, CT, 06340, USA.
¹² GSK, 1250 South Collegeville Road, Collegeville, PA, 19426, USA.
¹³ Alector, 151 Oyster Point Blvd #300, South San Francisco, CA, 94080, USA.
¹⁴ Allogene Therapeutics, 210 E. Grand Avenue, South San Francisco, CA, 94080, USA.
¹⁵ Bristol-Myers Squibb, 700 Bay Rd suite A, Redwood City, CA, 94063, USA.
¹⁶ Multitude Therapeutics, Abmart, 3698 Haven Avenue Suite A, Redwood City, CA, 94063, USA.

PMID: 31700121
PMCID: PMC6838164
DOI: 10.1038/s41598-019-53130-4

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

PubMed Disclaimer

Erratum for

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH. Zhu G, et al. Sci Rep. 2019 Jun 10;9(1):8420. doi: 10.1038/s41598-019-44874-0. Sci Rep. 2019. PMID: 31182754 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Affiliations

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Authors

Affiliations

Abstract

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources